| Issue 1073: August 27, 2013 TOP STORIES
IAC HANDOUTS VACCINE INFORMATION STATEMENTS
FEATURED RESOURCES JOURNAL ARTICLES AND NEWSLETTERS
EDUCATION AND TRAINING TOP STORIES Read Dr. Deborah Wexler's HHS blog post on the importance of giving the birth dose of hepatitis B vaccine The Department of Health and Human Services (HHS) recently posted a blog written by IAC Executive Director Dr. Deborah Wexler. Titled The End of Hepatitis B Transmission Begins at Birth, the post outlines important reasons for giving the hepatitis B birth dose to all newborns before hospital discharge. It also tells readers about IAC's new initiative, Give birth to the end of Hep B, which urges the nation's birthing institutions to adopt or strengthen their hepatitis B vaccine birth dose policies. For more information on IAC's birth dose initiative and related resources, see the next article in this issue of IAC Express titled "Apply for inclusion into IAC's Hepatitis B Birth Dose Honor Roll." The HHS blog is intended to be a dynamic, online conversation. An online comment form is available by scrolling down to the end of Dr. Wexler's post. Readers can read the post in more than 70 languages by clicking the icon titled "Translate" at the top of the blog post page. Back to Top Apply for inclusion into IAC's new Hepatitis B Birth Dose Honor Roll On July 16, 2013, the Immunization Action Coalition (IAC) launched the Hepatitis B Birth Dose Honor Roll. The honor roll recognizes hospitals and birthing centers that have attained high coverage rates for administering hepatitis B vaccine at birth and have met specific additional criteria. These criteria help define the important elements of a birth dose policy that are needed to ensure newborns do not fall through the cracks when medical errors occur. To be included in IAC's Hepatitis B Birth Dose Honor Roll, a birthing institution must have
In achieving a 99% coverage rate, Albany Medical Center, Albany, New York, became the first birth dose champion to be inducted into the honor roll at the initiative's July 16 launch event in Albany, New York. In addition to both recognition on IAC's Birth Dose Honor Roll and announcement of their achievement in IAC Express, honorees receive a color certificate suitable for framing. Related Links
New from IAC and ACOG! "Vaccinations for Pregnant Women" patient handout IAC, in partnership with the American College of Obstetricians and Gynecologists, recently developed Vaccinations for Pregnant Women. This patient handout informs pregnant women about which vaccinations are specifically recommended, which are allowed if indicated, and which are contraindicated during pregnancy. The information is presented in a simple table format that is easy to read and understand. "Vaccinations for Pregnant Women" is part of a suite of five handouts that focuses on adults in risk groups for vaccination. IAC will alert IAC Express readers as new adult handouts become available. Here are the four other handouts currently in the suite:
Back to top IAC Spotlight! Subscribing to IAC's free publications is quick work using shortened online form IAC has revised its online subscription form! Subscribing to all three IAC publications—IAC Express, Needle Tips, and Vaccinate Adults—has been made easier for you and your colleagues. To subscribe, simply enter your name and email address. It's that easy! Once you complete the sign-up form at www.immunize.org/subscribe, you'll start receiving weekly IAC Express issues and immediate email notification when new issues of Needle Tips and Vaccinate Adults are released online. Please share this message with colleagues who you think will appreciate receiving IAC's publications. Related Links Back to top FDA extends FluLaval IIV (GlaxoSmithKline) age range to include children and teens age 3–17 years; licenses quadrivalent FluLaval product On August 16, FDA approved a request by GlaxoSmithKline (GSK) to supplement its biologics license application for FluLaval trivalent inactivated influenza vaccine (IIV3) to include children and teens age 3 through 17 years. Previously, FluLaval IIV3 was licensed for the prevention of influenza disease in people age 18 years and older. On the same day, FDA approved GSK's request to supplement its biologics license application for FluLaval to include a quadrivalent inactivated influenza vaccine (IIV4) formulation. FluLaval IIV4 is licensed for the prevention of influenza disease in people age 3 years and older. Related Links
IAC HANDOUTS IAC and CDC revise vaccine storage temperature logs and add troubleshooting record with electronic functionality Over the past months, IAC and CDC staff collaborated to redesign vaccine storage temperature logs to match the newest vaccine storage and handling recommendations from CDC and improve the usability of these resources. Following is a summary of the changes IAC and CDC made:
VACCINE INFORMATION STATEMENTS CDC releases updated rotavirus VIS On August 26, CDC released an updated rotavirus Vaccine Information Statement (VIS). The most significant change is in the estimated rates of intussusception following vaccination. Because this change concerns a potential adverse event, providers should begin using the new VIS immediately. CDC will post an accompanying provider information sheet soon; IAC Express will notify readers when this is done. Related Links
IAC posts 27 additional influenza VIS translations IAC recently posted translations of both the inactivated influenza vaccine (IIV) VIS and the live attenuated influenza vaccine (LAIV) VIS in Armenian, Arabic, Cambodian, simplified Chinese, traditional Chinese, Farsi, French, Hmong, Korean, Russian, Somali, Tagalog, and Vietnamese. The IIV VIS is also available in Thai. Simplified Chinese is preferred in China, Singapore, and Malaysia. Traditional Chinese is preferred in Hong Kong, Macau, and Taiwan. IAC thanks the California Department of Public Health, Immunization Branch, for the Armenian, Cambodian, Farsi, Hmong, Korean and Tagalog translations, and Asian Pacific Health Care Venture of Los Angeles for the Thai translation. Related Links
IAC posts eight additional translations of the chickenpox (varicella) VIS and one more translation of the shingles VIS IAC recently posted translations of the chickenpox (varicella) VIS in Arabic, Armenian, Farsi, French, Korean, Tagalog, simplified Chinese, and traditional Chinese. Simplified Chinese is preferred in China, Singapore, and Malaysia. Traditional Chinese is preferred in Hong Kong, Macau, and Taiwan. In addition, the shingles (zoster) VIS is now available in simplified Chinese. Related Links
FEATURED RESOURCES Order IAC's popular full-size laminated versions of the 2013 U.S. immunization schedules today! IAC's laminated versions of the 2013 U.S. child/teen and adult immunization schedules are covered with a tough, washable coating that lets them stand up to a year's worth of use in every area of your healthcare setting where immunizations are given. Each has six pages (i.e., three double-sided pages) and is folded to measure 8.5" by 11".  
PRICING 1–4 copies: $7.50 each 5–19 copies: $5.50 each 20–99 copies: $4.50 each 100–499 copies: $4.00 each 500–999 copies: $3.50 each For quotes on customizing or placing orders for 1,000 copies or more, call (651) 647-9009 or email admininfo@immunize.org You can access specific information on both schedules, view images of both, order online, or download an order form at the Shop IAC: Laminated Schedules web page. Back to top JOURNAL ARTICLES AND NEWSLETTERS CDC publishes report on Japanese encephalitis in Asia and the Western Pacific CDC published Japanese Encephalitis Surveillance and Immunization—Asia and the Western Pacific, 2012 in the August 23 issue of MMWR (pages 658–662). The first paragraph is reprinted below. Japanese encephalitis (JE) virus is a leading cause of encephalitis in Asia, causing an estimated 67,900 JE cases annually. To control JE, the World Health Organization (WHO) recommends that JE vaccine be incorporated into immunization programs in all areas where JE is a public health problem. For many decades, progress mainly occurred in a small number of high-income Asian countries. Recently, prospects for control have improved with better disease burden awareness as a result of increased JE surveillance and wider availability of safe, effective vaccines. This report summarizes the status of JE surveillance and immunization programs in 2012 in Asia and the Western Pacific. Data were obtained from the WHO/United Nations Children's Fund (UNICEF) Joint Reporting Form (JRF), published literature, meeting reports, and websites. In 2012, 18 (75%) of the 24 countries with areas of JE virus transmission risk conducted at least some JE surveillance, and 11 (46%) had a JE immunization program. Further progress toward JE control requires increased awareness of disease burden at the national and regional levels, availability of WHO-prequalified pediatric JE vaccines, and international support for surveillance and vaccine introduction in countries with limited resources. Back to top CDC publishes article about polio vaccination in northern Nigeria CDC published Polio Field Census and Vaccination of Underserved Populations—Northern Nigeria, 2012–2013 in the August 23 issue of MMWR (pages 663–665). The beginning of the first paragraph is reprinted below. In 2012, the World Health Assembly declared completion of polio eradication a public health emergency. However, wild poliovirus (WPV) transmission remains endemic in three countries (Afghanistan, Nigeria, and Pakistan). In Nigeria, the National Stop Transmission of Polio (N-STOP) program, under the umbrella of the Nigerian Field Epidemiology and Laboratory Training Program (FELTP), has been developed to implement innovative strategies that address the remaining polio eradication challenges in Nigeria. One N-STOP initiative focuses on locating and vaccinating children aged <5 years in remote nomadic, scattered, and border populations in northern Nigeria, where low polio vaccination coverage likely contributes to ongoing WPV transmission. During August 2012–April 2013, N-STOP conducted field outreach activities that enumerated 40,212 remote settlements, including 4,613 (11.5%) settlements never visited by vaccination teams during previous polio supplemental immunization activities (SIAs). Enumeration resulted in documentation of 906,201 children aged <5 years residing in these settlements, including 53,738 (5.9%) who had never received polio vaccination, and in detection of 211 unreported cases of acute flaccid paralysis (AFP) with onset of illness in the 6 months before enumeration. Back to top EDUCATION AND TRAINING Reminder: New Jersey Immunization Network to offer August 28 webinar on the importance of the hepatitis B vaccine birth dose The New Jersey Immunization Network will present a 30-minute webinar about perinatal hepatitis B prevention, beginning at 1:00 p.m. (ET) on Wednesday, August 28. The webinar will feature Dr. Deborah L. Wexler, executive director, Immunization Action Coalition (IAC), talking about IAC's hepatitis birth dose initiative, Give birth to the end of Hep B, and related online guide, Hepatitis B: What Hospitals Need to Do to Protect Newborns. Access additional information on webinar content, as well as the registration form Do you have a hepatitis B birth dose question for Dr. Wexler? Submit your question with your webinar registration, or email it to Mary Jo Garofoli, program coordinator. Back to top  |
About IZ Express
IZ Express is supported in part by Grant No. 1NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer
ISSN 2771-8085
IZ Express Disclaimer
ISSN 2771-8085
Editorial Information
-
Editor-in-ChiefKelly L. Moore, MD, MPH
-
Managing EditorJohn D. Grabenstein, RPh, PhD
-
Associate EditorSharon G. Humiston, MD, MPH
-
Writer/Publication CoordinatorTaryn Chapman, MS
Courtnay Londo, MA -
Style and Copy EditorMarian Deegan, JD
-
Web Edition ManagersArkady Shakhnovich
Jermaine Royes -
Contributing WriterLaurel H. Wood, MPA
-
Technical ReviewerKayla Ohlde